Warfield Kelly Lyn, Olinger Gene Garrard
Vaccine Development, Integrated Biotherapeutics, Inc., 21 Firstfield Road Suite 100, Gaithersburg, MD 20878, USA.
J Biomed Biotechnol. 2011;2011:984241. doi: 10.1155/2011/984241. Epub 2011 Dec 28.
Infection with many emerging viruses, such as the hemorrhagic fever disease caused by the filoviruses, Marburg (MARV), and Ebola virus (EBOV), leaves the host with a short timeframe in which to mouse a protective immune response. In lethal cases, uncontrolled viral replication and virus-induced immune dysregulation are too severe to overcome, and mortality is generally associated with a lack of notable immune responses. Vaccination studies in animals have demonstrated an association of IgG and neutralizing antibody responses against the protective glycoprotein antigen with survival from lethal challenge. More recently, studies in animal models of filovirus hemorrhagic fever have established that induction of a strong filovirus-specific cytotoxic T lymphocyte (CTL) response can facilitate complete viral clearance. In this review, we describe assays used to discover CTL responses after vaccination or live filovirus infection in both animal models and human clinical trials. Unfortunately, little data regarding CTL responses have been collected from infected human survivors, primarily due to the low frequency of disease and the inability to perform these studies in the field. Advancements in assays and technologies may allow these studies to occur during future outbreaks.
感染许多新兴病毒,如由丝状病毒马尔堡病毒(MARV)和埃博拉病毒(EBOV)引起的出血热疾病,会使宿主在短时间内产生保护性免疫反应。在致死性病例中,不受控制的病毒复制和病毒诱导的免疫失调过于严重而无法克服,死亡率通常与缺乏显著的免疫反应有关。动物疫苗接种研究表明,针对保护性糖蛋白抗原的IgG和中和抗体反应与致死性攻击后的存活有关。最近,丝状病毒出血热动物模型的研究证实,诱导强烈的丝状病毒特异性细胞毒性T淋巴细胞(CTL)反应可促进病毒的完全清除。在这篇综述中,我们描述了在动物模型和人类临床试验中用于发现接种疫苗或感染活丝状病毒后CTL反应的检测方法。不幸的是,关于感染人类幸存者的CTL反应的数据很少,主要是因为疾病发生率低且无法在现场进行这些研究。检测方法和技术的进步可能会使这些研究在未来疫情爆发期间得以开展。